|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
185,611,000 |
Market
Cap: |
N/A |
Last
Volume: |
6,246,627 |
Avg
Vol: |
2,668,772 |
52
Week Range: |
$23.99 - $23.99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Berger Harvey J MD |
Chairman & CEO |
|
2015-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,800 |
1,383,862 |
|
- |
|
Fitzgerald Edward M |
Executive VP, CFO |
|
2015-05-01 |
4 |
AS |
$8.80 |
$528,000 |
D/D |
(60,000) |
305,852 |
|
- |
|
Fitzgerald Edward M |
Executive VP, CFO |
|
2015-05-01 |
4 |
OE |
$7.56 |
$453,600 |
D/D |
60,000 |
365,852 |
|
- |
|
Clackson Timothy P |
President, R&D, CSO |
|
2015-04-23 |
4 |
AS |
$9.50 |
$1,175,777 |
D/D |
(123,766) |
316,548 |
|
- |
|
Berger Harvey J MD |
Chairman & CEO |
|
2015-03-26 |
4 |
D |
$8.17 |
$1,039,175 |
D/D |
(127,194) |
1,343,460 |
|
- |
|
Berger Harvey J MD |
Chairman & CEO |
|
2015-03-26 |
4 |
OE |
$7.56 |
$1,134,000 |
D/D |
150,000 |
1,446,175 |
|
- |
|
Berstein David L |
SVP, Chief IP Counsel |
|
2015-03-23 |
4/A |
AS |
$8.56 |
$17,118 |
D/D |
(2,000) |
226,449 |
|
- |
|
Cantor Maria E |
SVP, Corporate Affairs and HR |
|
2015-03-23 |
4 |
AS |
$8.55 |
$34,491 |
D/D |
(4,033) |
104,881 |
|
- |
|
Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
|
2015-03-23 |
4 |
AS |
$8.55 |
$25,661 |
D/D |
(3,000) |
117,797 |
|
- |
|
Fitzgerald Edward M |
Executive VP, CFO |
|
2015-03-23 |
4 |
AS |
$8.55 |
$35,630 |
D/D |
(4,167) |
305,209 |
|
- |
|
Haluska Frank |
SVP, Clinical R&D, CMO |
|
2015-03-23 |
4 |
AS |
$8.55 |
$28,229 |
D/D |
(3,300) |
114,124 |
|
- |
|
Duvall Martin J |
EVP, CCO |
|
2015-03-23 |
4 |
AS |
$8.57 |
$7,145 |
D/D |
(834) |
54,950 |
|
- |
|
Clackson Timothy P |
President, R&D, CSO |
|
2015-03-23 |
4 |
AS |
$8.55 |
$57,016 |
D/D |
(6,667) |
440,314 |
|
- |
|
Clackson Timothy P |
President, R&D, CSO |
|
2015-03-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,333 |
446,981 |
|
- |
|
Berstein David L |
SVP, Chief IP Counsel |
|
2015-03-23 |
4 |
AS |
$8.56 |
$17,118 |
D/D |
(2,000) |
159,907 |
|
- |
|
Berstein David L |
SVP, Chief IP Counsel |
|
2015-03-20 |
4/A |
AS |
$8.85 |
$21,026 |
D/D |
(2,375) |
224,449 |
|
- |
|
Cantor Maria E |
SVP, Corporate Affairs and HR |
|
2015-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,333 |
108,916 |
|
- |
|
Cantor Maria E |
SVP, Corporate Affairs and HR |
|
2015-03-20 |
4 |
AS |
$8.85 |
$31,627 |
D/D |
(3,575) |
101,583 |
|
- |
|
Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
|
2015-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
120,797 |
|
- |
|
Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
|
2015-03-20 |
4 |
AS |
$8.85 |
$35,390 |
D/D |
(4,000) |
114,797 |
|
- |
|
Berger Harvey J MD |
Chairman & CEO |
|
2015-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,000 |
1,320,654 |
|
- |
|
Fitzgerald Edward M |
Executive VP, CFO |
|
2015-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,333 |
309,376 |
|
- |
|
Fitzgerald Edward M |
Executive VP, CFO |
|
2015-03-20 |
4 |
AS |
$8.84 |
$47,908 |
D/D |
(5,417) |
301,043 |
|
- |
|
Haluska Frank |
SVP, Clinical R&D, CMO |
|
2015-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
117,424 |
|
- |
|
Haluska Frank |
SVP, Clinical R&D, CMO |
|
2015-03-20 |
4 |
AS |
$8.85 |
$31,634 |
D/D |
(3,575) |
111,424 |
|
- |
|
218 Records found
|
|
Page 5 of 9 |
|
|